Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Traws Pharma, Inc.
Report date February 05, 2025 · Filed February 10, 2025
Section 16 reporting ended · disclosed 2025-02-10. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jun 20, 2024 20:25 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017636 · form4-06202024_080620.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary F2 · derivative.expiration_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:25 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | Tax withholdingCommon Stock | 2,221 | $0.47 | $1,043.87 |
DisclosureSEC source: 0001415889-24-017636 · form4-06202024_080620.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,255 Read SEC document |
| June 10, 2024 Filed Jun 20, 2024 20:25 UTC | Traws Pharma, Inc. TRAW · Entity 8032 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-017636 · form4-06202024_080620.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 21:40 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 2,591 | $0.90 | $2,331.90 |
DisclosureSEC source: 0001415889-24-008142 · form4-03152024_090303.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,976 Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:40 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 8,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008142 · form4-03152024_090303.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,334 Underlying: Common Stock · 8,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On March 13, 2023 the reporting person was granted 26,000 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. F2 · derivative.expiration_date: On March 13, 2023 the reporting person was granted 26,000 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 21:40 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 8,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-008142 · form4-03152024_090303.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003205 · form4-02092024_100205.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,900 Underlying: Common Stock · 6,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. F2 · derivative.expiration_date: On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 2,443 | $0.67 | $1,636.81 |
DisclosureSEC source: 0001415889-24-003205 · form4-02092024_100205.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,901 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 6,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-003205 · form4-02092024_100205.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 03, 2023 Filed Aug 4, 2023 20:45 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,422 | $1.02 | $1,450.44 |
DisclosureSEC source: 0001415889-23-011867 · form4-08042023_080826.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,444 Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:45 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-011867 · form4-08042023_080826.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,750 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 2, 2021 the reporting person was granted 14,250 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: On August 2, 2021 the reporting person was granted 14,250 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:45 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-011867 · form4-08042023_080826.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:54 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-009750 · form4-06132023_080619.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. F2 · derivative.expiration_date: On June 10, 2022 the reporting person was granted 16,500 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:54 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,575 | $1.14 | $1,790.78 |
DisclosureSEC source: 0001415889-23-009750 · form4-06132023_080619.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,116 Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 20:54 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-009750 · form4-06132023_080619.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:19 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004902 · form4-03142023_110331.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F3 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary F3 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:19 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 79,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001415889-23-004902 · form4-03142023_110331.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires 2033-03-13 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:56 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 6,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002167 · form4-02082023_100254.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Stock · 6,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. F2 · derivative.expiration_date: On February 7, 2022 the reporting person was granted 20,700 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary. Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:56 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,785 | $1.36 | $2,427.60 |
DisclosureSEC source: 0001415889-23-002167 · form4-02082023_100254.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,191 Read SEC document |
| February 07, 2023 Filed Feb 8, 2023 22:56 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 6,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-002167 · form4-02082023_100254.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Tax withholdingCommon Stock | 1,355 | $1.32 | $1,788.60 |
DisclosureSEC source: 0001415889-22-008261 · form4-08042022_010847.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,076 Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionRestricted Stock Units · Derivative | 4,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008261 · form4-08042022_010847.xml · derivative · entry 3 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 4,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 2, 2021 the reporting person was granted 14,250 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: On August 2, 2021 the reporting person was granted 14,250 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:38 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | Exercise / conversionCommon Stock | 4,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-008261 · form4-08042022_010847.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · CFO AND COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 20:03 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-003288 · edgar.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common stock · 16,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 20:03 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 50,250 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001179110-22-003288 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,250 Underlying: Common stock · 50,250 shares Expires 2032-06-10 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:33 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 20,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000961 · edgar.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,700 Underlying: Common stock · 20,700 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| February 07, 2022 Filed Feb 9, 2022 21:33 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 62,100 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001179110-22-000961 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,100 Underlying: Common stock · 62,100 shares Expires 2032-02-07 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:01 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantRestricted Stock Units · Derivative | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-007923 · edgar.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common stock · 14,250 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit is convertible into one share of common stock. F2 · derivative.exercise_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. F2 · derivative.expiration_date: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary. Read SEC document |
| August 02, 2021 Filed Aug 5, 2021 00:01 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 42,750 | $0.00 Strike: $5.19 | $0.00 |
DisclosureSEC source: 0001179110-21-007923 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,750 Underlying: Common stock · 42,750 shares Expires 2031-08-02 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 22:26 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 301,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001179110-21-002007 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,000 Underlying: Common Stock · 301,000 shares Expires 2031-02-17 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. F2 · derivative.underlying: These stock appreciation rights represent the right to receive a cash payment equal to the excess, if any, of (i) the fair market value of each underlying share of the Company's common stock, determined on the date of exercise minus (ii) the exercise price; provided, that in no event may the cash payment for each stock appreciation right exceed $1.03, which is the maximum price per share of $2.54, minus the base amount of $1.51, subject to adjustment in accordance with the terms of the award agreement. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 13:55 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 15,000 | $1.00 | $15,000.00 |
DisclosureSEC source: 0001179110-21-001784 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,213 Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 22:11 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 4,614 | $0.26 | $1,199.64 |
DisclosureSEC source: 0001179110-20-011470 · edgar.xml · nonDerivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,213 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 22:11 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 16,755 | $0.26 | $4,356.30 |
DisclosureSEC source: 0001179110-20-011470 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,599 Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 21:48 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Appreciation Right · Derivative | 543,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001179110-20-008212 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,000 Underlying: Common Stock · 543,000 shares Expires 2030-07-09 F1 · derivative.exercise_date: These stock appreciation rights vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| May 19, 2020 Filed May 20, 2020 13:09 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 21,000 | $0.36 | $7,560.00 |
DisclosureSEC source: 0001179110-20-006358 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,844 Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 14:06 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 65,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001179110-19-013138 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-12-20 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:50 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseWarrant (right to purchase) · Derivative | 87,500 | Not disclosed Strike: $0.20 | Not disclosed |
DisclosureSEC source: 0001179110-19-012056 · edgar.xml · derivative · entry 2 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2024-11-25 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 12:50 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 87,500 | $0.20 | $17,500.00 |
DisclosureSEC source: 0001179110-19-012056 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,844 F1 · price: The common stock and warrants were acquired in a public offering, by Onconova Therapeutics, Inc, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.20. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 21:26 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 384,950 | $0.00 Strike: $0.46 | $0.00 |
DisclosureSEC source: 0001179110-18-010010 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,950 Underlying: Common Stock · 384,950 shares Expires 2028-07-26 F1 · derivative.exercise_date: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 21:49 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 31,024 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001179110-18-000601 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,024 Underlying: Common Stock · 31,024 shares Expires 2028-01-03 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 19:11 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | PurchaseCommon Stock | 1,429 | $2.10 | $3,000.90 |
DisclosureSEC source: 0001179110-17-006249 · edgar.xml · nonDerivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,155 Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 18:35 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 19,413 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001179110-17-001044 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,413 Underlying: Common Stock · 19,413 shares Expires 2027-01-17 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:41 UTC | Traws Pharma, Inc. ONTX · Entity 8032 | GrantStock Option (right to purchase) · Derivative | 5,587 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001179110-16-033200 · edgar.xml · derivative · entry 1 Guerin Mark Patrick · CIK 0001607714 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,587 Underlying: Common Stock · 5,587 shares Expires 2026-12-15 F1 · derivative.exercise_date: These options vest over three years in 36 equal monthly installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.